Haleon: Cost Savings Over-Delivery and Cash Flow Visibility Support an Overweight in a Deteriorating Staples Landscape

Core Thesis

Haleon offers rare earnings visibility within European Staples. The company’s structural cost savings are consistently over-delivering, giving it the ability to invest in price gaps at a time when most peers lack that flexibility. Combined with >6% FY26 free cash flow yield (Staples average ~5%), superior margin expansion trajectory, and a clear path to <1x net debt/EBITDA by FY28, the risk/reward skew is favorable. We reiterate Overweight with a 440p price target (+29% upside).

What the Market Is Underestimating

The market focused on Q1 2026 organic sales growth (OSG) of 2.2%, where price outstripped volume – a composition typically penalized. Critically, two temporary factors caused this: currency and financing (C&F) headwinds subtracted 130bps. As C&F abates and Q2 2025 destock base effects fade, sales should sequentially improve, including a volume recovery. Meanwhile, the market has missed that Haleon’s productivity savings continue to run ahead of plan. This surplus enables incremental pricing investment even while the company delivers its HSD% EBIT growth target. Most European Staples cannot do this today. Consensus earnings for the sector are being cut; Haleon’s FY26 EBIT estimate is virtually unchanged (down only 0.2%).

Evidence Chain

1. Q1 OSG softness is transient; volume recovery is in sight.

• Q1 OSG was 2.2% (price contribution > volume). C&F drag 130bps.
• Q2 destock lap and declining C&F impact should drive sequential improvement in both volume and OSG.
• Implication: Revenue growth re-acceleration is likely, supporting margin expansion without requiring price-led compression.

2. Cost savings continue to over-deliver, funding pricing investment.

• Management explicitly stated (though not quantified) that productivity savings are exceeding targets.
• This creates a unique advantage vs. peers who are paring back spending to defend margins.
• Implication: Haleon can sustain A&P spending and price investments to gain share, while peers cannot.

3. Strong FCF yield and deleveraging provide downside protection.

• FY26 FCF yield >6% vs. Staples average ~5%.
• Net debt/EBITDA is projected to decline from 2.6x (FY25) to 0.9x (FY28e).
• Implication: The stock’s cash generation offers a valuation floor not available in most Staples names.

Key Risks

• Geopolitical / regional softness: Middle East (especially UAE) consumption has weakened following the Iran conflict. Management acknowledged this. SE Asia and African markets face high energy price and supply constraints. These could weigh on volume recovery.
• Cost savings execution: If productivity savings fail to materialize as planned, the pricing advantage evaporates and margin expansion slows.
• Private label competition: Increased share loss in OTC, VMS, or smoking cessation categories would pressure both volume and price/mix.

Valuation and Trade Implications

We set a 440p price target, a blended average of:

• DCF: £5.09 (WACC 7.9%, terminal growth +2.5%, 10-year +5% FCF CAGR, terminal margin ~28% in 2039).
• P/E: ~18.2x CY26e P/E, a ~10% premium to European Staples (justified by OSG and margin trajectory) and a ~15% discount to P&G.

At 340p, the stock trades on 16.4x CY26e P/E (vs. base case 21.3x) and offers 29% upside. The bull case (555p, 25.9x CY26e) assumes sustained high-end OSG and aggressive margin expansion. The bear case (330p, 16.3x) assumes private label pressure and stagnant margins. The FCF yield >6% provides a margin of safety absent in most Staples.

Implied action: Overweight. Haleon’s combination of cost-driven pricing flexibility, high FCF yield, and earnings resilience insufficiently reflected in the current price.

Appendix

Table 1: Estimate Changes (Haleon £m)

Table 2: Risk/Reward Snapshot